Pharmaceutical compositions including a portion of the C-terminus of FGF23

• US 9,272,017 B2
• Filed: 02/08/2013
• Issued: 03/01/2016
• Est. Priority Date: 10/30/2009
• Status: Active Grant

• Current Assignee: New York University
• Original Assignee: New York University
• Inventors: Mohammadi, Moosa, Goetz, Regina
• Primary Examiner(s): Saoud, Christine J
• Application Number:
  US13/763,301
• Publication Number:
  US 20130172275A1
• Time in Patent Office: 1,117 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: G01N 21/84 Systems specially adapted for particular applications
• CPC Class Codes: G01N 30/00 Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation G01N3/00, G01N5/00, G01N7/00, G01N9/00, G01N11/00, G01N13/00, G01N15/00, G01N17/00, G01N19/00, G01N21/00, G01N22/00, G01N23/00, G01N24/00, G01N25/00, G01N27/00, G01N29/00 take precedence
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

The present invention is directed to a pharmaceuticalm composition comprising a peptide comprising at least a portion corresponding to the C-terminus of FGF23 and an additive selected from the group consisting of vitamin D and a vitamin D receptor agonist.

Claims

1. A pharmaceutical composition comprising:

a peptide comprising at least a portion corresponding to the C-terminus of FGF23, wherein the portion corresponding to the C-terminus of FGF23 consists of the amino acid sequence of SEQ ID NO;

12 and

an additive, wherein the additive is a vitamin D receptor agonist and is formulated in combination with said peptide for simultaneous administration.

2. The pharmaceutical composition according to claim 1, wherein the peptide consists of SEQ ID NO:

12.

3. The pharmaceutical composition according to claim 1 further comprising a pharmaceutically acceptable carrier.

4. The pharmaceutical composition according to claim 1, wherein the composition is in the form of a tablet, capsule, powder, solution, suspension, or emulsion.

5. The pharmaceutical composition according to claim 1, wherein the composition is formulated for administration to a subject orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.

6. The pharmaceutical composition according to claim 1, wherein the additive is vitamin D.